Jonathan Barratt’s research is focused on the pathogenesis of IgA nephropathy and a range of areas across renal medicine including glomerular disease, multi-system renal disease and complications of chronic kidney disease, in particular renal-associated anaemia. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases and leads the Renal Research Group within the College of Life Sciences, University of Leicester. He also participates in other IgA nephrology initiatives such as the International IgA Nephropathy Network and in workgroups identifying endpoints for clinical trials such as the FDA and ASN Kidney Health Initiative. Professor Barratt has been a Principal Investigator for international randomized controlled clinical trials in IgA nephropathy and has attended both the FDA and EMA as an expert witness for new therapies in IgA nephropathy. He is an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology and sits on the Kidney Research UK Grants committee.
Dana V. Rizk's clinical and research interests revolve around glomerular diseases and, in particular IgA Nephropathy. She is the principal investigator of several clinical trials and is part of multi-disciplinary translational research projects focused on the role of biomarkers in IgAN. She serves as the Director of Clinical Trials Research in the Division and as the Medical Director of the Clinical Trials Administrative Office on campus. On the education side, she is involved in residents' and fellows’ training and serves on the clinical competency committees of both programs. She has mentored many trainees in clinical research and has received numerous teaching awards. Dr. Rizk is a member-elect of the Southern Society of Clinical Investigation and is past President of the Southern American Federation of Medical Research.
